GoKawiilThank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Dose once, treat forever: drugs are being engineered to last much longer
Why This Matters
The article's body wasn't available (only a browser-compatibility notice loaded), so only the headline premise can be assessed: drug developers are engineering therapies designed to last far longer, potentially shifting medicine toward single-dose or infrequent treatments. If borne out, that trend matters for adherence, cost and access, and it is also a reminder that paywalled or script-heavy science sites often fail to deliver content to readers.
Key Takeaways
- Headline claim: drugs are increasingly being engineered for much longer duration, up to dose-once approaches.
- No supporting details were retrievable from the page, so specific science, companies or timelines can't be verified here.
- Long-acting formulations would chiefly affect patient adherence, dosing frequency and treatment logistics.
Get alerts for these topics